Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Radiodermatitis 3Head and Neck Neoplasms 3Hypotension 2Stroke 1Shock, Septic 1Optimal Tissue Perfusion 1Neoplasms 1Mouth Neoplasms 1Leiomyoma 1Brain Neoplasms 1Alopecia 1

Interventions

pembrolizumab 185Gemcitabine 170Paclitaxel 152Carboplatin 137Bevacizumab 128Surveys and Questionnaires 118Cisplatin 115Docetaxel 114Blood Specimen Collection 110Cyclophosphamide 109Exercise 108Nivolumab 98Fluorouracil 90Capecitabine 86Dexamethasone 81Radiotherapy 80Irinotecan 74Standard of Care 69Pemetrexed 68Oxaliplatin 68Leucovorin 64Drug Therapy 64Cetuximab 60Erlotinib Hydrochloride 56Sorafenib 53atezolizumab 52Ipilimumab 51Doxorubicin 50trametinib 47Interviews as Topic 47

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms × Norepinephrine × Clear all
NCT06711432 2024-12-02

PRECISION

Zhejiang Cancer Hospital

Phase NA Recruiting
214 enrolled

Neoplasms, Stroke

Data powered by HemOnc (CC BY 4.0) Colophon âš¡